Business Review Board

Members from two different advisory groups, the Scientific Review Board and the Business Review Board, review all grant applications submitted to the ADDF. The Business Review Board comprises members from various backgrounds, including venture capital and the biotechnology and pharmaceutical industry.

  • Thomas Cirrito, PhD
    Stemline Therapeutics, Inc.

  • Mark A. Cochran, PhD
    Johns Hopkins University School of Medicine

  • Steven G. Dickman
    CBT Advisors

  • Julie Eskay-Eagle
    Vice President of Strategy and Corporate Development, Real Endpoints

  • Stephen M. Goodman, Esq.
    Pryor Cashman Sherman & Flynn, LLP

  • Allan M. Green, MD, PhD, JD
    Allan M. Green Esq., LLC

  • Michael J. Gutch, PhD
    MedImmune Ventures

  • Emer Leahy, PhD
    Psychogenics Inc.

  • Michael Lefenfeld
    SiGNa Chemistry, Inc.

  • David Lowe, PhD
    NeuroAssets

  • Brian McCarthy, PhD
    Influmedix, Inc.

  • Ian J. Mehr, PhD
    Golden Pine Ventures, LLC

  • Daniel J. O'Connell
    NeuroVentures Capital, LLC

  • Michael Parker
    BioAsset Advisors

  • Rana Quraishi, PhD
    Capco